-
Voice of China at EBMT 2026 | Professor Shan Fu: Ultra-Low Dose Achieves 91.7% Complete Remission—IL-10 CAR-T Therapy Demonstrates the Potential of “Enhanced Efficacy with Reduced Dose”
From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
-
Voice of China at EBMT | Professor Yanmin Zhao: Pre-Transplant Genetic MRD Monitoring Improves Risk Stratification in TP53-Mutated AML/MDS
From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
-
Voice of China at EBMT | Dr. Jingjing Feng: Dual-Target CD19/BCMA CAR-T Therapy Opens New Hope for Neuromyelitis Optica Spectrum Disorder
From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
-
Professor Ming Hou: From “Following” to “Leading”—Key Updates in the 2025 Chinese Guidelines for Adult Immune Thrombocytopenia
In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and…
-
Professor Liansheng Zhang: A Common Condition with Major Consequences—Current Challenges and New Strategies in the Management of Iron Deficiency Anemia
Iron deficiency anemia (IDA) is the most common nutritional deficiency and the leading cause of anemia worldwide. Despite the availability of well-established diagnostic methods, IDA is often underestimated in clinical practice as a “minor condition.”
-
Professor Xiaohui Zhang: Building on 25 Years of Progress—Advancing High-Quality Development in Hematologic Immunology
In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026, coinciding with the 25th anniversary of the Hematology and Immunology Branch of the Chinese Society of Immunology.
-
Professor Hongmei Jing: From Nature Breakthroughs to Clinical Practice—Advances in Precision Diagnosis and Treatment of Lymphoma
In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and…
-
Professor Zonghong Shao：Immune Dysregulation in Myelodysplastic Syndromes and Clinical Management Strategies
In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and…
Connecting Medical Expertise through Media